BridgeBio Pharma (BBIO) Equity Ratio (2018 - 2026)

BridgeBio Pharma has disclosed Equity Ratio across 9 years of filings, most recently posting 1.65 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 1.65, up 10.99% year-over-year; the trailing twelve-month figure through Mar 2026 was 1.65 (up 10.99% YoY), and the FY2025 annual result was 2.23, down 40.59% from the prior year.
• Equity Ratio came in at 1.65 for Q1 2026 at BridgeBio Pharma, up from 2.23 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 1.18 in Q2 2022 to a low of 2.68 in Q2 2023.
• The 5-year median for Equity Ratio is 1.82 (2023), against an average of 1.78.
• Across the five-year window, Equity Ratio slumped 259.48% in 2022 and jumped 49.19% in 2024, its largest moves.
• BridgeBio Pharma's Equity Ratio stood at 2.0 in 2022, then dropped by 23.17% to 2.46 in 2023, then soared by 35.49% to 1.59 in 2024, then plunged by 40.59% to 2.23 in 2025, then grew by 25.79% to 1.65 in 2026.
• The last three Equity Ratio figures came in at 1.65 (Q1 2026), 2.23 (Q4 2025), and 1.94 (Q3 2025), per Business Quant data.